138 related articles for article (PubMed ID: 25540066)
1. Improved prediction of clinical outcome in chronic myeloid leukemia.
Ćojbašić I; Mačukanović-Golubović L; Mihailović D; Vučić M; Lukić S
Int J Hematol; 2015 Feb; 101(2):173-83. PubMed ID: 25540066
[TBL] [Abstract][Full Text] [Related]
2. Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients.
Iacobucci I; Saglio G; Rosti G; Testoni N; Pane F; Amabile M; Poerio A; Soverini S; Bassi S; Cilloni D; Bassan R; Breccia M; Lauria F; Izzo B; Merante S; Frassoni F; Paolini S; Montefusco E; Baccarani M; Martinelli G;
Clin Cancer Res; 2006 May; 12(10):3037-42. PubMed ID: 16707599
[TBL] [Abstract][Full Text] [Related]
3. Can the Use of Bone Marrow Parameters Improve the Efficacy of Risk Prediction Scores in Chronic Myeloid Leukemia in Imatinib Era?
Kanakasetty GB; Thanky AH; Kuntegowdanahalli L; Dasappa L; Jacob L; Mallekavu SB; Lakkavalli R; Kadabur L; Antapura R
Clin Lymphoma Myeloma Leuk; 2017 Jun; 17(6):375-381. PubMed ID: 28502460
[TBL] [Abstract][Full Text] [Related]
4. Predictive parameters for imatinib failure in patients with chronic myeloid leukemia.
Lekovic D; Gotic M; Milic N; Zivojinovic B; Jovanovic J; Colovic N; Milosevic V; Bogdanovic A
Hematology; 2017 Sep; 22(8):460-466. PubMed ID: 28327053
[TBL] [Abstract][Full Text] [Related]
5. The EUTOS prognostic score: review and validation in 1288 patients with CML treated frontline with imatinib.
Hoffmann VS; Baccarani M; Lindoerfer D; Castagnetti F; Turkina A; Zaritsky A; Hellmann A; Prejzner W; Steegmann JL; Mayer J; Indrak K; Colita A; Rosti G; Pfirrmann M
Leukemia; 2013 Oct; 27(10):2016-22. PubMed ID: 23752173
[TBL] [Abstract][Full Text] [Related]
6. EUTOS CML prognostic scoring system predicts ELN-based 'event-free survival' better than Euro/Hasford and Sokal systems in CML patients receiving front-line imatinib mesylate.
Uz B; Buyukasik Y; Atay H; Kelkitli E; Turgut M; Bektas O; Eliacik E; Isik A; Aksu S; Goker H; Sayinalp N; Ozcebe OI; Haznedaroglu IC
Hematology; 2013 Sep; 18(5):247-52. PubMed ID: 23540886
[TBL] [Abstract][Full Text] [Related]
7. The significance of angiogenesis for predicting optimal therapeutic response in chronic myeloid leukaemia patients.
Ćojbašić I; Mačukanović-Golubović L; Mihailović D; Vučić M; Ćojbašić Ž
Pol J Pathol; 2017; 68(3):241-251. PubMed ID: 29363916
[TBL] [Abstract][Full Text] [Related]
8. Prognostic discrimination based on the EUTOS long-term survival score within the International Registry for Chronic Myeloid Leukemia in children and adolescents.
Millot F; Guilhot J; Suttorp M; Güneş AM; Sedlacek P; De Bont E; Li CK; Kalwak K; Lausen B; Culic S; Dworzak M; Kaiserova E; De Moerloose B; Roula F; Biondi A; Baruchel A
Haematologica; 2017 Oct; 102(10):1704-1708. PubMed ID: 28838993
[TBL] [Abstract][Full Text] [Related]
9. Long-term outcome of complete cytogenetic responders after imatinib 400 mg in late chronic phase, philadelphia-positive chronic myeloid leukemia: the GIMEMA Working Party on CML.
Palandri F; Iacobucci I; Martinelli G; Amabile M; Poerio A; Testoni N; Soverini S; Castagnetti F; De Vivo A; Breccia M; Specchia G; Abruzzese E; Martino B; Cilloni D; Saglio G; Pane F; Liberati AM; Rosti G; Baccarani M;
J Clin Oncol; 2008 Jan; 26(1):106-11. PubMed ID: 18165644
[TBL] [Abstract][Full Text] [Related]
10. Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha.
Merx K; Müller MC; Kreil S; Lahaye T; Paschka P; Schoch C; Weisser A; Kuhn C; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
Leukemia; 2002 Sep; 16(9):1579-83. PubMed ID: 12200666
[TBL] [Abstract][Full Text] [Related]
11. Treatment and outcome of 2904 CML patients from the EUTOS population-based registry.
Hoffmann VS; Baccarani M; Hasford J; Castagnetti F; Di Raimondo F; Casado LF; Turkina A; Zackova D; Ossenkoppele G; Zaritskey A; Höglund M; Simonsson B; Indrak K; Sninska Z; Sacha T; Clark R; Bogdanovic A; Hellmann A; Griskevicius L; Schubert-Fritschle G; Sertic D; Guilhot J; Lejniece S; Zupan I; Burgstaller S; Koskenvesa P; Everaus H; Costeas P; Lindoerfer D; Rosti G; Saussele S; Hochhaus A; Hehlmann R
Leukemia; 2017 Mar; 31(3):593-601. PubMed ID: 27568522
[TBL] [Abstract][Full Text] [Related]
12. Treatment of Philadelphia-positive chronic myeloid leukemia with imatinib: importance of a stable molecular response.
Palandri F; Iacobucci I; Soverini S; Castagnetti F; Poerio A; Testoni N; Alimena G; Breccia M; Rege-Cambrin G; Tiribelli M; Varaldo R; Abruzzese E; Martino B; Luciano L; Pane F; Saglio G; Martinelli G; Baccarani M; Rosti G
Clin Cancer Res; 2009 Feb; 15(3):1059-63. PubMed ID: 19188180
[TBL] [Abstract][Full Text] [Related]
13. Limited clinical value of regular bone marrow cytogenetic analysis in imatinib-treated chronic phase CML patients monitored by RQ-PCR for BCR-ABL.
Ross DM; Branford S; Moore S; Hughes TP
Leukemia; 2006 Apr; 20(4):664-70. PubMed ID: 16482210
[TBL] [Abstract][Full Text] [Related]
14. Chronic myeloid leukemia following therapy with imatinib mesylate (Gleevec). Bone marrow histopathology and correlation with genetic status.
Frater JL; Tallman MS; Variakojis D; Druker BJ; Resta D; Riley MB; Hrisinko MA; Peterson LC
Am J Clin Pathol; 2003 Jun; 119(6):833-41. PubMed ID: 12817431
[TBL] [Abstract][Full Text] [Related]
15. EUTOS score predicts long-term outcome but not optimal response to imatinib in patients with chronic myeloid leukaemia.
Tiribelli M; Bonifacio M; Calistri E; Binotto G; Maino E; Marin L; Guardalben E; Branca A; Gherlinzoni F; Semenzato G; Sancetta R; Pizzolo G; Fanin R
Leuk Res; 2013 Nov; 37(11):1457-60. PubMed ID: 23993428
[TBL] [Abstract][Full Text] [Related]
16. Pattern of chronic myeloid leukemia in the imatinib era in a Sub-Saharan African setting.
Faye BF; Dieng N; Seck M; Gadji M; Gueye YB; Sy D; Toure SA; Sall A; Toure AO; Dieye TN; Diop S
Ann Hematol; 2016 Oct; 95(10):1603-10. PubMed ID: 27370991
[TBL] [Abstract][Full Text] [Related]
17. Analysis of the impact of imatinib mesylate therapy on the prognosis of patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha regimens for early chronic phase.
Kantarjian H; O'Brien S; Cortes J; Shan J; Giles F; Garcia-Manero G; Verstovsek S; Faderl S; Rios MB; Talpaz M
Cancer; 2003 Oct; 98(7):1430-7. PubMed ID: 14508830
[TBL] [Abstract][Full Text] [Related]
18. Additional cytogenetic abnormalities and variant t(9;22) at the diagnosis of childhood chronic myeloid leukemia: The experience of the International Registry for Chronic Myeloid Leukemia in Children and Adolescents.
Millot F; Dupraz C; Guilhot J; Suttorp M; Brizard F; Leblanc T; Güneş AM; Sedlacek P; De Bont E; Li CK; Kalwak K; Lausen B; Culic S; Dworzak M; Kaiserova E; De Moerloose B; Roula F; Biondi A; Baruchel A; Guilhot F
Cancer; 2017 Sep; 123(18):3609-3616. PubMed ID: 28497898
[TBL] [Abstract][Full Text] [Related]
19. The EUTOS score identifies chronic myeloid leukeamia patients with poor prognosis treated with imatinib first or second line.
Breccia M; Finsinger P; Loglisci G; Latagliata R; Mancini M; Salaroli A; Serrao A; Zacheo I; Alimena G
Leuk Res; 2012 Sep; 36(9):e209-10. PubMed ID: 22770911
[No Abstract] [Full Text] [Related]
20. [Efficacy and safety analysis of interferon combined with imatinib in treating chronic myeloid leukemia].
Liu Y; Bao EN; Zhong WW; Lu XC; Zhu HL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Apr; 22(2):304-9. PubMed ID: 24762996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
